Publications - Page 24 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP) 31/08/23
The SOCE Machinery: An Unbalanced Knowledge between Left and Right Ventricular Pathophysiology.

Sabourin J, Beauvais A, Luo R, Montani D, Benitah JP, Masson B, Antigny F.

Cells. 2022 Oct 18;11(20):3282.
Hypertension pulmonaire (HTP) 31/08/23
Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension.

Masson B, Le Ribeuz H, Sabourin J, Laubry L, Woodhouse E, Foster R, Ruchon Y, Dutheil M, Boët A, Ghigna MR, De Montpreville VT, Mercier O, Beech DJ, Benitah JP, Bailey MA, Humbert M, Montani D, Capuano V, Antigny F.

Circ Res. 2022 Oct 14;131(9):e102-e119.
Hypertension pulmonaire (HTP) 31/08/23
Long-term outcomes of transcatheter Potts shunt in children with suprasystemic pulmonary arterial hypertension.

Haddad RN, Levy M, Szezepanski I, Malekzadeh-Milani S, Bonnet D.

Front Cardiovasc Med. 2022 Oct 26;9:1028304.
Hypertension pulmonaire (HTP) 31/08/23
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.

Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C, Chaouat A, Cottin V, De Groote P, Favrolt N, Horeau-Langlard D, Magro P, Savale L, Prévot G, Renard S, Sitbon O, Parent F, Trésorier R, Tromeur C, Piedvache C, Grimaldi L, Fadel E, Montani D, Humbert M, Simonneau G.

Lancet Respir Med. 2022 Oct;10(10):961-971.
Hypertension pulmonaire (HTP) 31/08/23
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group.

Eur Heart J. 2022 Oct 11;43(38):3618-3731.
Hypertension pulmonaire (HTP) 31/08/23
Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT, and is associated with pulmonary hypertension.

Tian S, Cai Z, Sen P, van Uden D, van de Kamp E, Thuillet R, Tu L, Guignabert C, Boomars K, Van der Heiden K, Brandt MM, Merkus D.

Am J Physiol Heart Circ Physiol. 2022 Nov 1;323(5):H958-H974.
Hypertension pulmonaire (HTP) 31/08/23
4D flow cardiovascular magnetic resonance recovery profiles following pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.

Dong ML, Azarine A, Haddad F, Amsallem M, Kim YW, Yang W, Fadel E, Aubrege L, Loecher M, Ennis D, Pavec JL, Vignon-Clementel I, Feinstein JA, Mercier O, Marsden AL.

J Cardiovasc Magn Reson. 2022 Nov 14;24(1):59.
Hypertension pulmonaire (HTP) 31/08/23
Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report.

Triantafyllidi H, Iordanidis D, Montani D, Samiotis E, Mademli M, Vlachos S, Mpahara A, Humbert M, Dorfmuller P, Tsagkaris I, Iliodromitis E.

Respir Med Res. 2022 Nov;82:100943.
Hypertension pulmonaire (HTP) 31/08/23
Molecular Function and Contribution of TBX4 in Development and Disease.

Karolak JA, Welch CL, Mosimann C, Bzdega K, West JD, Montani D, Eyries M, Mullen MP, Abman SH, Prapa M, Gräf S, Morrell NW, Hemnes AR, Perros F, Hamid R, Logan MPO, Whitsett J, Galambos C, Stankiewicz P, Chung WK, Austin ED; TBX4Life Initiative.

Am J Respir Crit Care Med. 2022 Nov 11.
Hypertension pulmonaire (HTP) 31/08/23
First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.

Riou M, Canuet M, Ghigna MR, Eyries M, Chenard MP, Porzio M, Olland A, Humbert M, Kessler R, Montani D.

Eur Respir J. 2022 Nov 3;60(5):2201197.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

The SOCE Machinery: An Unbalanced Knowledge between Left and Right Ventricular Pathophysiology.

Orai1 Inhibitors as Potential Treatments for Pulmonary Arterial Hypertension.

Long-term outcomes of transcatheter Potts shunt in children with suprasystemic pulmonary arterial hypertension.

Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

Loss of lung microvascular endothelial Piezo2 expression impairs NO synthesis, induces EndMT, and is associated with pulmonary hypertension.

4D flow cardiovascular magnetic resonance recovery profiles following pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.

Pulmonary veno-occlusive disease associated with long-term occupational exposure to chemical solvents and pesticides. A case report.

Molecular Function and Contribution of TBX4 in Development and Disease.

First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant.